These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28700424)

  • 1. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
    Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
    Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
    Pinto A; Mackrides N; Nadji M
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
    Kernochan LE; Garcia RL
    J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
    Costa MJ; Guinee D
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).
    Holmes BJ; Gown AM; Vang R; Ronnett BM; Yemelyanova A
    Int J Gynecol Pathol; 2014 Jul; 33(4):425-31. PubMed ID: 24901404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.
    Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K
    Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
    Buza N; Tavassoli FA
    Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.
    Kounelis S; Jones MW; Papadaki H; Bakker A; Swalsky P; Finkelstein SD
    Hum Pathol; 1998 Jan; 29(1):82-7. PubMed ID: 9445138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
    de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
    Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine Carcinosarcomas - Diagnosis and Management.
    Denschlag D; Ulrich UA
    Oncol Res Treat; 2018; 41(11):675-679. PubMed ID: 30317231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endometrial adenocarcinoma.
    Meis JM; Lawrence WD
    Am J Clin Pathol; 1990 Jul; 94(1):1-7. PubMed ID: 1694389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
    Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
    Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of mixed Müllerian tumours.
    D'Angelo E; Prat J
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):705-18. PubMed ID: 21742560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sarcomas and mixed mesodermal tumors of the uterus].
    Günthert AR
    Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
    Seidman JD; Chauhan S
    Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
    Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
    Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
    Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
    Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal.
    Mayall F; Rutty K; Campbell F; Goddard H
    Histopathology; 1994 Mar; 24(3):211-4. PubMed ID: 8200622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight cases of malignant mixed Müllerian tumor (carcinosarcoma) of the uterus: findings in SurePath™ cervical cytology.
    Gupta N; Dudding N; Smith JH
    Diagn Cytopathol; 2014 Feb; 42(2):165-9. PubMed ID: 22865798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
    Semczuk A; Skomra D; Chyzyńska M; Szewczuk W; Olcha P; Korobowicz E
    Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.